Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients

The MATRICS Consensus Cognitive Battery (MCCB) was developed to assess cognitive treatment effects in schizophrenia clinical trials, and is considered the FDA gold standard outcome measure for that purpose. The aim of the present study was to establish pre-treatment psychometric characteristics of t...

Full description

Saved in:
Bibliographic Details
Published inSchizophrenia research Vol. 190; pp. 172 - 179
Main Authors Georgiades, Anastasia, Davis, Vicki G., Atkins, Alexandra S., Khan, Anzalee, Walker, Trina W., Loebel, Antony, Haig, George, Hilt, Dana C., Dunayevich, Eduardo, Umbricht, Daniel, Sand, Michael, Keefe, Richard S.E.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.12.2017
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The MATRICS Consensus Cognitive Battery (MCCB) was developed to assess cognitive treatment effects in schizophrenia clinical trials, and is considered the FDA gold standard outcome measure for that purpose. The aim of the present study was to establish pre-treatment psychometric characteristics of the MCCB in a large pooled sample. The dataset included 2616 stable schizophrenia patients enrolled in 15 different clinical trials between 2007 and 2016 within the United States (94%) and Canada (6%). The MCCB was administered twice prior to the initiation of treatment in 1908 patients. Test-retest reliability and practice effects of the cognitive composite score, the neurocognitive composite score, which excludes the domain Social Cognition, and the subtests/domains were examined using Intra-Class Correlations (ICC) and Cohen's d. Simulated regression models explored which domains explained the greatest portion of variance in composite scores. Test-retest reliability was high (ICC=0.88) for both composite scores. Practice effects were small for the cognitive (d=0.15) and neurocognitive (d=0.17) composites. Simulated bootstrap regression analyses revealed that 3 of the 7 domains explained 86% of the variance for both composite scores. The domains that entered most frequently in the top 3 positions of the regression models were Speed of Processing, Working Memory, and Visual Learning. Findings provide definitive psychometric characteristics and a benchmark comparison for clinical trials using the MCCB. The test-retest reliability of the MCCB composite scores is considered excellent and the learning effects are small, fulfilling two of the key criteria for outcome measures in cognition clinical trials.
AbstractList The MATRICS Consensus Cognitive Battery (MCCB) was developed to assess cognitive treatment effects in schizophrenia clinical trials, and is considered the FDA gold standard outcome measure for that purpose. The aim of the present study was to establish pre-treatment psychometric characteristics of the MCCB in a large pooled sample. The dataset included 2616 stable schizophrenia patients enrolled in 15 different clinical trials between 2007 and 2016 within the United States (94%) and Canada (6%). The MCCB was administered twice prior to the initiation of treatment in 1908 patients. Test-retest reliability and practice effects of the cognitive composite score, the neurocognitive composite score, which excludes the domain Social Cognition, and the subtests/domains were examined using Intra-Class Correlations (ICC) and Cohen's d. Simulated regression models explored which domains explained the greatest portion of variance in composite scores. Test-retest reliability was high (ICC=0.88) for both composite scores. Practice effects were small for the cognitive (d=0.15) and neurocognitive (d=0.17) composites. Simulated bootstrap regression analyses revealed that 3 of the 7 domains explained 86% of the variance for both composite scores. The domains that entered most frequently in the top 3 positions of the regression models were Speed of Processing, Working Memory, and Visual Learning. Findings provide definitive psychometric characteristics and a benchmark comparison for clinical trials using the MCCB. The test-retest reliability of the MCCB composite scores is considered excellent and the learning effects are small, fulfilling two of the key criteria for outcome measures in cognition clinical trials.The MATRICS Consensus Cognitive Battery (MCCB) was developed to assess cognitive treatment effects in schizophrenia clinical trials, and is considered the FDA gold standard outcome measure for that purpose. The aim of the present study was to establish pre-treatment psychometric characteristics of the MCCB in a large pooled sample. The dataset included 2616 stable schizophrenia patients enrolled in 15 different clinical trials between 2007 and 2016 within the United States (94%) and Canada (6%). The MCCB was administered twice prior to the initiation of treatment in 1908 patients. Test-retest reliability and practice effects of the cognitive composite score, the neurocognitive composite score, which excludes the domain Social Cognition, and the subtests/domains were examined using Intra-Class Correlations (ICC) and Cohen's d. Simulated regression models explored which domains explained the greatest portion of variance in composite scores. Test-retest reliability was high (ICC=0.88) for both composite scores. Practice effects were small for the cognitive (d=0.15) and neurocognitive (d=0.17) composites. Simulated bootstrap regression analyses revealed that 3 of the 7 domains explained 86% of the variance for both composite scores. The domains that entered most frequently in the top 3 positions of the regression models were Speed of Processing, Working Memory, and Visual Learning. Findings provide definitive psychometric characteristics and a benchmark comparison for clinical trials using the MCCB. The test-retest reliability of the MCCB composite scores is considered excellent and the learning effects are small, fulfilling two of the key criteria for outcome measures in cognition clinical trials.
The MATRICS Consensus Cognitive Battery (MCCB) was developed to assess cognitive treatment effects in schizophrenia clinical trials, and is considered the FDA gold standard outcome measure for that purpose. The aim of the present study was to establish pre-treatment psychometric characteristics of the MCCB in a large pooled sample. The dataset included 2616 stable schizophrenia patients enrolled in 15 different clinical trials between 2007 and 2016 within the United States (94%) and Canada (6%). The MCCB was administered twice prior to the initiation of treatment in 1908 patients. Test-retest reliability and practice effects of the cognitive composite score, the neurocognitive composite score, which excludes the domain Social Cognition, and the subtests/domains were examined using Intra-Class Correlations (ICC) and Cohen's d. Simulated regression models explored which domains explained the greatest portion of variance in composite scores. Test-retest reliability was high (ICC=0.88) for both composite scores. Practice effects were small for the cognitive (d=0.15) and neurocognitive (d=0.17) composites. Simulated bootstrap regression analyses revealed that 3 of the 7 domains explained 86% of the variance for both composite scores. The domains that entered most frequently in the top 3 positions of the regression models were Speed of Processing, Working Memory, and Visual Learning. Findings provide definitive psychometric characteristics and a benchmark comparison for clinical trials using the MCCB. The test-retest reliability of the MCCB composite scores is considered excellent and the learning effects are small, fulfilling two of the key criteria for outcome measures in cognition clinical trials.
Abstract The MATRICS Consensus Cognitive Battery (MCCB) was developed to assess cognitive treatment effects in schizophrenia clinical trials, and is considered the FDA gold standard outcome measure for that purpose. The aim of the present study was to establish pre-treatment psychometric characteristics of the MCCB in a large pooled sample. The dataset included 2616 stable schizophrenia patients enrolled in 15 different clinical trials between 2007 and 2016 within the United States (94%) and Canada (6%). The MCCB was administered twice prior to the initiation of treatment in 1908 patients. Test-retest reliability and practice effects of the cognitive composite score, the neurocognitive composite score, which excludes the domain Social Cognition, and the subtests/domains were examined using Intra-Class Correlations (ICC) and Cohen's d . Simulated regression models explored which domains explained the greatest portion of variance in composite scores. Test-retest reliability was high (ICC = 0.88) for both composite scores. Practice effects were small for the cognitive ( d = 0.15) and neurocognitive ( d = 0.17) composites. Simulated bootstrap regression analyses revealed that 3 of the 7 domains explained 86% of the variance for both composite scores. The domains that entered most frequently in the top 3 positions of the regression models were Speed of Processing, Working Memory, and Visual Learning. Findings provide definitive psychometric characteristics and a benchmark comparison for clinical trials using the MCCB. The test-retest reliability of the MCCB composite scores is considered excellent and the learning effects are small, fulfilling two of the key criteria for outcome measures in cognition clinical trials.
Author Georgiades, Anastasia
Umbricht, Daniel
Keefe, Richard S.E.
Loebel, Antony
Davis, Vicki G.
Hilt, Dana C.
Walker, Trina W.
Khan, Anzalee
Haig, George
Atkins, Alexandra S.
Sand, Michael
Dunayevich, Eduardo
Author_xml – sequence: 1
  givenname: Anastasia
  surname: Georgiades
  fullname: Georgiades, Anastasia
  organization: NeuroCog Trials, Durham, NC, USA
– sequence: 2
  givenname: Vicki G.
  surname: Davis
  fullname: Davis, Vicki G.
  organization: NeuroCog Trials, Durham, NC, USA
– sequence: 3
  givenname: Alexandra S.
  surname: Atkins
  fullname: Atkins, Alexandra S.
  organization: NeuroCog Trials, Durham, NC, USA
– sequence: 4
  givenname: Anzalee
  surname: Khan
  fullname: Khan, Anzalee
  organization: NeuroCog Trials, Durham, NC, USA
– sequence: 5
  givenname: Trina W.
  surname: Walker
  fullname: Walker, Trina W.
  organization: NeuroCog Trials, Durham, NC, USA
– sequence: 6
  givenname: Antony
  surname: Loebel
  fullname: Loebel, Antony
  organization: Sunovion Pharmaceuticals Inc, USA
– sequence: 7
  givenname: George
  surname: Haig
  fullname: Haig, George
  organization: Abbvie, USA
– sequence: 8
  givenname: Dana C.
  surname: Hilt
  fullname: Hilt, Dana C.
  organization: FORUM pharma, USA
– sequence: 9
  givenname: Eduardo
  surname: Dunayevich
  fullname: Dunayevich, Eduardo
  organization: Takeda, USA
– sequence: 10
  givenname: Daniel
  surname: Umbricht
  fullname: Umbricht, Daniel
  organization: F. Hoffmann-La Roche Ltd, USA
– sequence: 11
  givenname: Michael
  surname: Sand
  fullname: Sand, Michael
  organization: Boehringer-Ingelheim, USA
– sequence: 12
  givenname: Richard S.E.
  orcidid: 0000-0002-0173-8897
  surname: Keefe
  fullname: Keefe, Richard S.E.
  email: richard.keefe@duke.edu
  organization: NeuroCog Trials, Durham, NC, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28433500$$D View this record in MEDLINE/PubMed
BookMark eNqVkktv1DAUhS1URKeFf4CQl2wSrmPnhRBSGfGoVASiZW05zk3jIWOntqfSsOOf4zCFBRKqWPkuvnN8dc49IUfWWSTkKYOcAatebPKgR48hL4DVOfAcBDwgK1bWPCtKaI_ICtoCsratxDE5CWEDAKyE-hE5LhrBeQmwIj8-h70e3RajN5rqUXmlI3oTotGBuoHGEenHs6sv5-tLunY2oA27kKZra6K5RfpGxcTvqbFU0Un5a6SzcxP2VLvR-bh4hKi6CWna13x3c1raGkVnFQ3aGB6Th4OaAj65e0_J13dvr9YfsotP78_XZxeZFjXErOlqLupCDG2LhYCSqW5QVS0UVp1iDWO17nUPYmBMlaIa-KA4V0XXV6wZkNf8lDw_-M7e3ewwRLk1QeM0KYtuFyRrWiZK0UKb0Gd36K7bYi9nb7bK7-Xv2BIgDoD2LgSPwx-EgVzakRt5aEcu7UjgMrWTZC__kmkTUwzORq_MdJ_49UGMKaRbgz5BKUCNvfGoo-yd-V8DPRlrtJq-4R7Dxu28TQVIJkMhQV4u17McD6s5sOZXLK_-bXD__z8BX_TYWw
CitedBy_id crossref_primary_10_30773_pi_2020_0306
crossref_primary_10_1093_arclin_acaa004
crossref_primary_10_1192_j_eurpsy_2022_2316
crossref_primary_10_3389_fpsyt_2018_00356
crossref_primary_10_1016_j_scog_2019_01_001
crossref_primary_10_1016_j_scog_2022_100270
crossref_primary_10_1177_20451253241302603
crossref_primary_10_3389_fpsyt_2019_00648
crossref_primary_10_1177_0269881119855302
crossref_primary_10_1016_j_scog_2019_100171
crossref_primary_10_1016_S2215_0366_20_30513_7
crossref_primary_10_1038_s41398_023_02593_1
crossref_primary_10_1093_schbul_sbac065
crossref_primary_10_1002_hbm_24976
crossref_primary_10_4103_indianjpsychiatry_indianjpsychiatry_690_24
crossref_primary_10_1016_j_jpsychires_2022_10_069
crossref_primary_10_1016_j_jpsychires_2024_03_014
crossref_primary_10_3389_fnhum_2021_777043
crossref_primary_10_1080_13854046_2021_1962410
crossref_primary_10_1016_j_heliyon_2024_e25915
crossref_primary_10_1016_j_schres_2017_05_009
crossref_primary_10_1016_j_psychres_2024_116121
crossref_primary_10_1016_j_psychres_2022_114479
crossref_primary_10_1016_j_schres_2020_11_018
crossref_primary_10_1093_schbul_sbae051
crossref_primary_10_1093_schbul_sbae151
crossref_primary_10_1177_02698811211000778
crossref_primary_10_1093_schbul_sby049
crossref_primary_10_1016_j_scog_2024_100310
crossref_primary_10_1016_j_schres_2024_04_007
crossref_primary_10_1038_s41398_022_02254_9
crossref_primary_10_1186_s12888_019_2018_6
crossref_primary_10_1016_j_schres_2020_08_008
crossref_primary_10_1093_schbul_sbae191
crossref_primary_10_1016_j_bpsc_2018_06_008
crossref_primary_10_1007_s00406_020_01200_4
Cites_doi 10.1016/S0920-9964(02)00425-5
10.1176/appi.ajp.2014.14070936
10.1016/j.biopsych.2010.09.052
10.1016/j.jagp.2012.10.011
10.1176/appi.ajp.2008.07071135
10.1001/archpsyc.58.1.24
10.1093/oxfordjournals.schbul.a033430
10.1615/CritRevNeurobiol.v14.i1.10
10.1016/j.schres.2004.09.004
10.1176/appi.ajp.2007.07010042
10.1037/0033-2909.133.5.833
10.1016/j.schres.2011.11.026
10.1037/0021-9010.92.2.373
10.1016/j.biopsych.2005.01.003
10.1093/schbul/sbn037
10.1016/j.biopsych.2004.06.023
10.1016/j.schres.2011.11.001
10.1017/S1355617703930074
10.1037/0894-4105.12.3.426
10.1016/j.schres.2010.09.015
10.1176/appi.ajp.2007.07010043
10.1038/npp.2008.200
10.1037/a0019026
ContentType Journal Article
Copyright 2017 Elsevier B.V.
Elsevier B.V.
Copyright © 2017 Elsevier B.V. All rights reserved.
Copyright_xml – notice: 2017 Elsevier B.V.
– notice: Elsevier B.V.
– notice: Copyright © 2017 Elsevier B.V. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.schres.2017.03.040
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic


MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 1573-2509
EndPage 179
ExternalDocumentID 28433500
10_1016_j_schres_2017_03_040
S0920996417301809
1_s2_0_S0920996417301809
Genre Clinical Trial
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIMH NIH HHS
  grantid: N01 MH90001
GroupedDBID ---
--K
--M
-~X
.1-
.FO
.GJ
.~1
0R~
123
1B1
1P~
1RT
1~.
1~5
4.4
457
4G.
4H-
53G
5VS
7-5
71M
8P~
9JM
9JO
AABNK
AADFP
AAEDT
AAEDW
AAGJA
AAGUQ
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAWTL
AAXKI
AAXLA
AAXUO
AAYWO
ABBQC
ABCQJ
ABFNM
ABIVO
ABJNI
ABMAC
ABMZM
ABOYX
ABWVN
ABXDB
ACDAQ
ACGFS
ACHQT
ACIEU
ACIUM
ACRLP
ACRPL
ACVFH
ACXNI
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGUBO
AGWIK
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HEG
HMK
HMO
HMQ
HMW
HVGLF
HZ~
IHE
J1W
KOM
M29
M2V
M39
M3V
M41
MO0
MOBAO
N9A
O-L
O9-
OAUVE
OH0
OKEIE
OU-
OZT
P-8
P-9
P2P
PC.
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SNS
SPCBC
SPS
SSB
SSH
SSN
SSY
SSZ
T5K
WUQ
Z5R
~G-
AACTN
AFCTW
AFKWA
AJOXV
AMFUW
RIG
AADPK
AAIAV
ABLVK
ABYKQ
AFYLN
AJBFU
EFLBG
LCYCR
AAYXX
AGRNS
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c470t-8b734724f99e24051abfa674ae6ba18117cdcd04f11a546f3fa33a2bd618fe373
IEDL.DBID .~1
ISSN 0920-9964
1573-2509
IngestDate Fri Jul 11 12:26:36 EDT 2025
Wed Feb 19 02:42:37 EST 2025
Thu Apr 24 22:59:30 EDT 2025
Tue Jul 01 04:00:54 EDT 2025
Fri Feb 23 02:32:19 EST 2024
Sun Feb 23 10:19:46 EST 2025
Tue Aug 26 19:42:06 EDT 2025
IsPeerReviewed true
IsScholarly true
Keywords Schizophrenia
MATRICS Consensus Cognitive Battery
Cognition
Language English
License Copyright © 2017 Elsevier B.V. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c470t-8b734724f99e24051abfa674ae6ba18117cdcd04f11a546f3fa33a2bd618fe373
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ORCID 0000-0002-0173-8897
PMID 28433500
PQID 1891454909
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_1891454909
pubmed_primary_28433500
crossref_primary_10_1016_j_schres_2017_03_040
crossref_citationtrail_10_1016_j_schres_2017_03_040
elsevier_sciencedirect_doi_10_1016_j_schres_2017_03_040
elsevier_clinicalkeyesjournals_1_s2_0_S0920996417301809
elsevier_clinicalkey_doi_10_1016_j_schres_2017_03_040
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-12-01
PublicationDateYYYYMMDD 2017-12-01
PublicationDate_xml – month: 12
  year: 2017
  text: 2017-12-01
  day: 01
PublicationDecade 2010
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Schizophrenia research
PublicationTitleAlternate Schizophr Res
PublicationYear 2017
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Collie, Maruff, Darby, McStephen (bb0025) 2003; 9
Javitt, Buchanan, Keefe, Kern, McMahon, Green, Lieberman, Goff, Csernansky, McEvoy, Jarskog, Seidman, Gold, Kimhy, Nolan, Barch, Ball, Robinson, Marder (bb0070) 2012; 136
Rajji, Voineskos, Butters, Miranda, Arenovich, Menon, Ismail, Kern, Mulsant (bb0105) 2013; 21
Keefe, Eesley, Poe (bb0075) 2005; 57
Green, Harris, Nuechterlein (bb0050) 2014; 171
Rodriguez-Jimenez, Bagney, Garcia-Navarro, Aparicio, Lopez-Anton, Moreno-Ortega, Jimenez-Arriero, Santos, Lobo, Kern, Green, Nuechterlein, Palomo (bb0115) 2012; 134
Buchanan, Keefe, Lieberman, Barch, Csernansky, Goff, Gold, Green, Jarskog, Javitt, Kimhy, Kraus, McEvoy, Mesholam-Gately, Seidman, Ball, McMahon, Kern, Robinson, Marder (bb0015) 2011; 69
Nuechterlein, Green, Kern, Baade, Barch, Cohen, Essock, Fenton, Frese, Gold, Goldberg, Heaton, Keefe, Kraemer, Mesholam-Gately, Seidman, Stover, Weinberger, Young, Zalcman, Marder (bb0100) 2008; 165
Barch, Carter, Committee (bb0005) 2008; 34
Heinrichs, Zakzanis (bb0065) 1998; 12
Hausknecht, Halpert, Di Paolo, Moriarty Gerrard (bb0055) 2007; 92
Freedman, Olincy, Buchanan, Harris, Gold, Johnson, Allensworth, Guzman-Bonilla, Clement, Ball, Kutnick, Pender, Martin, Stevens, Wagner, Zerbe, Soti, Kem (bb0035) 2008; 165
Keefe, Fox, Harvey, Cucchiaro, Siu, Loebel (bb0080) 2011; 125
Cohen (bb0020) 1977
Green, Kern, Braff, Mintz (bb0040) 2000; 26
Lieberman, Papadakis, Csernansky, Litman, Volavka, Jia, Gage, Group, M.-M.-S (bb0095) 2009; 34
Salthouse (bb0120) 2010; 24
Kern, Green, Nuechterlein, Deng (bb0085) 2004; 72
Kern, Nuechterlein, Green, Baade, Fenton, Gold, Keefe, Mesholam-Gately, Mintz, Seidman, Stover, Marder (bb0090) 2008; 165
Heaton, Gladsjo, Palmer, Kuck, Marcotte, Jeste (bb0060) 2001; 58
Beglinger, Ahmed, Derby, Siemers, Fastenau, Crawford-Miller, Shekhar, Kareken (bb0010) 2003; 62
Elvevag, Goldberg (bb0030) 2000; 14
Green, Nuechterlein, Gold, Barch, Cohen, Essock, Fenton, Frese, Goldberg, Heaton, Keefe, Kern, Kraemer, Stover, Weinberger, Zalcman, Marder (bb0045) 2004; 56
Reichenberg, Harvey (bb0110) 2007; 133
Kern (10.1016/j.schres.2017.03.040_bb0085) 2004; 72
Cohen (10.1016/j.schres.2017.03.040_bb0020) 1977
Collie (10.1016/j.schres.2017.03.040_bb0025) 2003; 9
Elvevag (10.1016/j.schres.2017.03.040_bb0030) 2000; 14
Hausknecht (10.1016/j.schres.2017.03.040_bb0055) 2007; 92
Javitt (10.1016/j.schres.2017.03.040_bb0070) 2012; 136
Salthouse (10.1016/j.schres.2017.03.040_bb0120) 2010; 24
Freedman (10.1016/j.schres.2017.03.040_bb0035) 2008; 165
Nuechterlein (10.1016/j.schres.2017.03.040_bb0100) 2008; 165
Buchanan (10.1016/j.schres.2017.03.040_bb0015) 2011; 69
Heinrichs (10.1016/j.schres.2017.03.040_bb0065) 1998; 12
Green (10.1016/j.schres.2017.03.040_bb0040) 2000; 26
Beglinger (10.1016/j.schres.2017.03.040_bb0010) 2003; 62
Rajji (10.1016/j.schres.2017.03.040_bb0105) 2013; 21
Barch (10.1016/j.schres.2017.03.040_bb0005) 2008; 34
Rodriguez-Jimenez (10.1016/j.schres.2017.03.040_bb0115) 2012; 134
Keefe (10.1016/j.schres.2017.03.040_bb0075) 2005; 57
Kern (10.1016/j.schres.2017.03.040_bb0090) 2008; 165
Heaton (10.1016/j.schres.2017.03.040_bb0060) 2001; 58
Green (10.1016/j.schres.2017.03.040_bb0050) 2014; 171
Keefe (10.1016/j.schres.2017.03.040_bb0080) 2011; 125
Lieberman (10.1016/j.schres.2017.03.040_bb0095) 2009; 34
Green (10.1016/j.schres.2017.03.040_bb0045) 2004; 56
Reichenberg (10.1016/j.schres.2017.03.040_bb0110) 2007; 133
References_xml – volume: 171
  start-page: 1151
  year: 2014
  end-page: 1154
  ident: bb0050
  article-title: The MATRICS consensus cognitive battery: what we know 6
  publication-title: Am. J. Psychiatry
– volume: 58
  start-page: 24
  year: 2001
  end-page: 32
  ident: bb0060
  article-title: Stability and course of neuropsychological deficits in schizophrenia
  publication-title: Arch. Gen. Psychiatry
– volume: 165
  start-page: 203
  year: 2008
  end-page: 213
  ident: bb0100
  article-title: The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity
  publication-title: Am. J. Psychiatry
– volume: 72
  start-page: 11
  year: 2004
  end-page: 19
  ident: bb0085
  article-title: NIMH-MATRICS survey on assessment of neurocognition in schizophrenia
  publication-title: Schizophr. Res.
– volume: 21
  start-page: 108
  year: 2013
  end-page: 118
  ident: bb0105
  article-title: Cognitive performance of individuals with schizophrenia across seven decades: a study using the MATRICS Consensus Cognitive Battery
  publication-title: Am. J. Geriatr. Psychiatry
– year: 1977
  ident: bb0020
  article-title: Statistical Power Analysis for the Behavioral Sciences
– volume: 125
  start-page: 161
  year: 2011
  end-page: 168
  ident: bb0080
  article-title: Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial
  publication-title: Schizophr. Res.
– volume: 92
  start-page: 373
  year: 2007
  end-page: 385
  ident: bb0055
  article-title: Retesting in selection: a meta-analysis of coaching and practice effects for tests of cognitive ability
  publication-title: J. Appl. Psychol.
– volume: 62
  start-page: 191
  year: 2003
  end-page: 194
  ident: bb0010
  article-title: Neuropsychological practice effects and change detection in people with schizophrenia
  publication-title: Schizophr. Res.
– volume: 34
  start-page: 1322
  year: 2009
  end-page: 1329
  ident: bb0095
  article-title: A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia
  publication-title: Neuropsychopharmacology
– volume: 133
  start-page: 833
  year: 2007
  end-page: 858
  ident: bb0110
  article-title: Neuropsychological impairments in schizophrenia: integration of performance-based and brain imaging findings
  publication-title: Psychol. Bull.
– volume: 26
  start-page: 119
  year: 2000
  end-page: 136
  ident: bb0040
  article-title: Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?
  publication-title: Schizophr. Bull.
– volume: 165
  start-page: 214
  year: 2008
  end-page: 220
  ident: bb0090
  article-title: The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization
  publication-title: Am. J. Psychiatry
– volume: 14
  start-page: 1
  year: 2000
  end-page: 21
  ident: bb0030
  article-title: Cognitive impairment in schizophrenia is the core of the disorder
  publication-title: Crit. Rev. Neurobiol.
– volume: 57
  start-page: 688
  year: 2005
  end-page: 691
  ident: bb0075
  article-title: Defining a cognitive function decrement in schizophrenia
  publication-title: Biol. Psychiatry
– volume: 134
  start-page: 279
  year: 2012
  end-page: 284
  ident: bb0115
  article-title: The MATRICS Consensus Cognitive Battery (MCCB): co-norming and standardization in Spain
  publication-title: Schizophr. Res.
– volume: 136
  start-page: 25
  year: 2012
  end-page: 31
  ident: bb0070
  article-title: Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia
  publication-title: Schizophr. Res.
– volume: 34
  start-page: 613
  year: 2008
  end-page: 618
  ident: bb0005
  article-title: Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: a report of the second consensus building conference of the CNTRICS initiative
  publication-title: Schizophr. Bull.
– volume: 24
  start-page: 563
  year: 2010
  end-page: 572
  ident: bb0120
  article-title: Influence of age on practice effects in longitudinal neurocognitive change
  publication-title: Neuropsychology
– volume: 12
  start-page: 426
  year: 1998
  end-page: 445
  ident: bb0065
  article-title: Neurocognitive deficit in schizophrenia: a quantitative review of the evidence
  publication-title: Neuropsychology
– volume: 69
  start-page: 442
  year: 2011
  end-page: 449
  ident: bb0015
  article-title: A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia
  publication-title: Biol. Psychiatry
– volume: 165
  start-page: 1040
  year: 2008
  end-page: 1047
  ident: bb0035
  article-title: Initial phase 2 trial of a nicotinic agonist in schizophrenia
  publication-title: Am. J. Psychiatry
– volume: 9
  start-page: 419
  year: 2003
  end-page: 428
  ident: bb0025
  article-title: The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals
  publication-title: J. Int. Neuropsychol. Soc.
– volume: 56
  start-page: 301
  year: 2004
  end-page: 307
  ident: bb0045
  article-title: Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria
  publication-title: Biol. Psychiatry
– volume: 62
  start-page: 191
  issue: 1–2
  year: 2003
  ident: 10.1016/j.schres.2017.03.040_bb0010
  article-title: Neuropsychological practice effects and change detection in people with schizophrenia
  publication-title: Schizophr. Res.
  doi: 10.1016/S0920-9964(02)00425-5
– volume: 171
  start-page: 1151
  issue: 11
  year: 2014
  ident: 10.1016/j.schres.2017.03.040_bb0050
  article-title: The MATRICS consensus cognitive battery: what we know 6years later
  publication-title: Am. J. Psychiatry
  doi: 10.1176/appi.ajp.2014.14070936
– volume: 69
  start-page: 442
  issue: 5
  year: 2011
  ident: 10.1016/j.schres.2017.03.040_bb0015
  article-title: A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia
  publication-title: Biol. Psychiatry
  doi: 10.1016/j.biopsych.2010.09.052
– volume: 21
  start-page: 108
  issue: 2
  year: 2013
  ident: 10.1016/j.schres.2017.03.040_bb0105
  article-title: Cognitive performance of individuals with schizophrenia across seven decades: a study using the MATRICS Consensus Cognitive Battery
  publication-title: Am. J. Geriatr. Psychiatry
  doi: 10.1016/j.jagp.2012.10.011
– volume: 165
  start-page: 1040
  issue: 8
  year: 2008
  ident: 10.1016/j.schres.2017.03.040_bb0035
  article-title: Initial phase 2 trial of a nicotinic agonist in schizophrenia
  publication-title: Am. J. Psychiatry
  doi: 10.1176/appi.ajp.2008.07071135
– volume: 58
  start-page: 24
  issue: 1
  year: 2001
  ident: 10.1016/j.schres.2017.03.040_bb0060
  article-title: Stability and course of neuropsychological deficits in schizophrenia
  publication-title: Arch. Gen. Psychiatry
  doi: 10.1001/archpsyc.58.1.24
– volume: 26
  start-page: 119
  issue: 1
  year: 2000
  ident: 10.1016/j.schres.2017.03.040_bb0040
  article-title: Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?
  publication-title: Schizophr. Bull.
  doi: 10.1093/oxfordjournals.schbul.a033430
– volume: 14
  start-page: 1
  issue: 1
  year: 2000
  ident: 10.1016/j.schres.2017.03.040_bb0030
  article-title: Cognitive impairment in schizophrenia is the core of the disorder
  publication-title: Crit. Rev. Neurobiol.
  doi: 10.1615/CritRevNeurobiol.v14.i1.10
– volume: 72
  start-page: 11
  issue: 1
  year: 2004
  ident: 10.1016/j.schres.2017.03.040_bb0085
  article-title: NIMH-MATRICS survey on assessment of neurocognition in schizophrenia
  publication-title: Schizophr. Res.
  doi: 10.1016/j.schres.2004.09.004
– year: 1977
  ident: 10.1016/j.schres.2017.03.040_bb0020
– volume: 165
  start-page: 203
  issue: 2
  year: 2008
  ident: 10.1016/j.schres.2017.03.040_bb0100
  article-title: The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity
  publication-title: Am. J. Psychiatry
  doi: 10.1176/appi.ajp.2007.07010042
– volume: 133
  start-page: 833
  issue: 5
  year: 2007
  ident: 10.1016/j.schres.2017.03.040_bb0110
  article-title: Neuropsychological impairments in schizophrenia: integration of performance-based and brain imaging findings
  publication-title: Psychol. Bull.
  doi: 10.1037/0033-2909.133.5.833
– volume: 134
  start-page: 279
  issue: 2–3
  year: 2012
  ident: 10.1016/j.schres.2017.03.040_bb0115
  article-title: The MATRICS Consensus Cognitive Battery (MCCB): co-norming and standardization in Spain
  publication-title: Schizophr. Res.
  doi: 10.1016/j.schres.2011.11.026
– volume: 92
  start-page: 373
  issue: 2
  year: 2007
  ident: 10.1016/j.schres.2017.03.040_bb0055
  article-title: Retesting in selection: a meta-analysis of coaching and practice effects for tests of cognitive ability
  publication-title: J. Appl. Psychol.
  doi: 10.1037/0021-9010.92.2.373
– volume: 57
  start-page: 688
  issue: 6
  year: 2005
  ident: 10.1016/j.schres.2017.03.040_bb0075
  article-title: Defining a cognitive function decrement in schizophrenia
  publication-title: Biol. Psychiatry
  doi: 10.1016/j.biopsych.2005.01.003
– volume: 34
  start-page: 613
  issue: 4
  year: 2008
  ident: 10.1016/j.schres.2017.03.040_bb0005
  article-title: Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: a report of the second consensus building conference of the CNTRICS initiative
  publication-title: Schizophr. Bull.
  doi: 10.1093/schbul/sbn037
– volume: 56
  start-page: 301
  issue: 5
  year: 2004
  ident: 10.1016/j.schres.2017.03.040_bb0045
  article-title: Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria
  publication-title: Biol. Psychiatry
  doi: 10.1016/j.biopsych.2004.06.023
– volume: 136
  start-page: 25
  issue: 1–3
  year: 2012
  ident: 10.1016/j.schres.2017.03.040_bb0070
  article-title: Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia
  publication-title: Schizophr. Res.
  doi: 10.1016/j.schres.2011.11.001
– volume: 9
  start-page: 419
  issue: 3
  year: 2003
  ident: 10.1016/j.schres.2017.03.040_bb0025
  article-title: The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals
  publication-title: J. Int. Neuropsychol. Soc.
  doi: 10.1017/S1355617703930074
– volume: 12
  start-page: 426
  issue: 3
  year: 1998
  ident: 10.1016/j.schres.2017.03.040_bb0065
  article-title: Neurocognitive deficit in schizophrenia: a quantitative review of the evidence
  publication-title: Neuropsychology
  doi: 10.1037/0894-4105.12.3.426
– volume: 125
  start-page: 161
  issue: 2–3
  year: 2011
  ident: 10.1016/j.schres.2017.03.040_bb0080
  article-title: Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial
  publication-title: Schizophr. Res.
  doi: 10.1016/j.schres.2010.09.015
– volume: 165
  start-page: 214
  issue: 2
  year: 2008
  ident: 10.1016/j.schres.2017.03.040_bb0090
  article-title: The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization
  publication-title: Am. J. Psychiatry
  doi: 10.1176/appi.ajp.2007.07010043
– volume: 34
  start-page: 1322
  issue: 5
  year: 2009
  ident: 10.1016/j.schres.2017.03.040_bb0095
  article-title: A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia
  publication-title: Neuropsychopharmacology
  doi: 10.1038/npp.2008.200
– volume: 24
  start-page: 563
  issue: 5
  year: 2010
  ident: 10.1016/j.schres.2017.03.040_bb0120
  article-title: Influence of age on practice effects in longitudinal neurocognitive change
  publication-title: Neuropsychology
  doi: 10.1037/a0019026
SSID ssj0001507
Score 2.423521
Snippet The MATRICS Consensus Cognitive Battery (MCCB) was developed to assess cognitive treatment effects in schizophrenia clinical trials, and is considered the FDA...
Abstract The MATRICS Consensus Cognitive Battery (MCCB) was developed to assess cognitive treatment effects in schizophrenia clinical trials, and is considered...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 172
SubjectTerms Adult
Age Factors
Cognition
Computer Simulation
Female
Humans
Male
MATRICS Consensus Cognitive Battery
Neuropsychological Tests
Psychiatry
Psychometrics
Regression Analysis
Reproducibility of Results
Schizophrenia
Schizophrenia - diagnosis
Schizophrenic Psychology
Sex Factors
Title Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0920996417301809
https://www.clinicalkey.es/playcontent/1-s2.0-S0920996417301809
https://dx.doi.org/10.1016/j.schres.2017.03.040
https://www.ncbi.nlm.nih.gov/pubmed/28433500
https://www.proquest.com/docview/1891454909
Volume 190
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT8MwDI4QXLggEO-XgsS1rF3SpD1OE9MGggMPiVuUpIk0NDpEx4ELEv8cu015CBCI2zrVzVo79ufus03IodFO-FzqSPiuiMDh2SgX0kRaFsw5jBgWX-ifnYvhNT-5SW_mSL-thUFaZfD9jU-vvXX4phOeZud-PO5cxjmWfQqeoJFmdREf5xKt_Oj5neaBgKfutwdpEp7dls_VHC9IICGpRYKXrFud4iuQ78PTT_CzDkODZbIU8CPtNT9xhcy5cpW8NG7sDqdjWWo_92CmU08B5dGz3tXFqH9JcUQnzreo4FOgDtGmy-YTHZdU0wmSwynO3nIFxQG6DzO8BsBIM3G0-sjSo6Eta7VGrgfHV_1hFGYrRJbLeBZlRjIuu9znuYOgnibaeC0kB9UZnWD1qS1sEXOfJDrlwjOvGdNdU4gk845Jtk7my2npNgnVBQhzy42DbDETIgOIlxcMoJ-QPrZui7D2kSobGo_j_IuJahlmt6pRhEJFqJgpUMQWid6k7pvGG7-cn7baUm1RKbhBBZHhFzn5nZyrwl6uVKKqrorVF3v7KPnJZP-w5kFrTgp2M_5Fo0s3fYS1sjzhkLLj1TcaO3u7ewASjKVxvP3vdXfIIh41bJxdMj97eHR7gKlmZr_eNPtkoTc6HZ6_AugCIno
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT-MwELUqOMBlBVqWr4U10l5Dk9qxkyOqQGWX9gBF4mbZji11VVJEyoELEv98ZxIHWi0ItLcqzcRNZjzzJn0zQ8hPo53wudSR8D0RgcOzUS6kibQsmHMYMSy-0B-OxOCa_7pJbzqk39bCIK0y-P7Gp9feOhzphqfZvZtMuldxjmWfgidopBkW8a1y2L44xuD46ZXngYinbrgHeRKe3tbP1SQvyCAhq0WGl6x7neI7kLfj03v4s45DZxvkSwCQ9KT5jZuk48qv5LnxY7c4HstSu9yEmc48BZhHhyfjy_P-FcUZnTjgooJPgTtEmzabj3RSUk2nyA6nOHzLFRQn6N7P8RqAI83U0WqRpkdDX9Zqi1yfnY77gygMV4gsl_E8yoxkXPa4z3MHUT1NtPFaSA66MzrB8lNb2CLmPkl0yoVnXjOme6YQSeYdk-wbWSlnpdshVBcgzC03DtLFTIgMMF5eMMB-QvrYul3C2keqbOg8jgMwpqqlmP1RjSIUKkLFTIEidkn0InXXdN744Py01ZZqq0rBDyoIDR_IybfkXBU2c6USVfVUrP4xuEXJJZv9xJpHrTkp2M74H40u3ewB1sryhEPOjlffbuzs5e4BSTCWxvHef6_7g6wNxsMLdXE--r1P1vGbhprznazM7x_cAQCsuTmsN9BfT9AkCA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Psychometric+characteristics+of+the+MATRICS+Consensus+Cognitive+Battery+in+a+large+pooled+cohort+of+stable+schizophrenia+patients&rft.jtitle=Schizophrenia+research&rft.au=Georgiades%2C+Anastasia&rft.au=Davis%2C+Vicki+G&rft.au=Atkins%2C+Alexandra+S&rft.au=Khan%2C+Anzalee&rft.date=2017-12-01&rft.issn=0920-9964&rft_id=info:doi/10.1016%2Fj.schres.2017.03.040&rft.externalDBID=ECK1-s2.0-S0920996417301809&rft.externalDocID=1_s2_0_S0920996417301809
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0920-9964&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0920-9964&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0920-9964&client=summon